Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluoro-exendin-4
- Development stage
- Preclinical
- Lead developer
- University of Turku
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
fluoro-exendin-4 (specifically [18F]fluoro-exendin-4 or [18F]F-dibenzocyclooctyne-exendin-4) is a fluorine-18 labeled radiopharmaceutical peptide tracer developed by the Turku PET Centre (University of Turku and Åbo Akademi University). It is designed to target the glucagon-like peptide-1 receptor (GLP-1R), which is highly expressed on pancreatic beta cells. The tracer is utilized in positron emission tomography (PET) imaging for the non-invasive quantification of pancreatic beta-cell mass, the localization of insulinomas, the diagnosis of congenital hyperinsulinism, and the monitoring of stem cell-derived islet grafts. By utilizing a strain-promoted click chemistry synthesis strategy, the tracer achieves high specific activity and exhibits rapid renal clearance, reducing the radiation dose to the kidneys compared to radiometal-labeled exendin analogs.
- Other names
- [18F]F-dibenzocyclooctyne-exendin-4[18F]exendin[18F]exendin-4[18F]fluoro-exendin-4[18F]fluoroexendin-4Nle14,Cys40(mal-dPEG(4)-DBCO-azide-PEG4[18F]fluoroexendin-4)fluoro-exendin-4fluoro-exendin4fluoro-exendin 4
02
Targets
Beyond the preview
Go deeper on fluoro-exendin-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluoro-exendin-4.